European Journal of Pharmacology, 200 (1991) 381–384
© 1991 Elsevier Science Publishers B.V. 0014-2999/91/$03.50

Author index

Abe, N., see Tanaka, Y. (200) 353
Ahlenius, S., Larsson, K. and Wijkström, A.
Behavioral and biochemical effects of the 5-HT_{1A} receptor agonists flesinoxan and 8-OH-DPAT in the rat (200) 259
Ahrén, B., see Gregersen, H. (200) 365
Al-Tikriti, M., see Innis, R. (200) 369
Antoine, M.-H., see Lebrun, P. (200) 159
Armstrong, P.W., see Forster, C. (200) 251
Asahina, T., see Tanaka, Y. (200) 353

Baba, A., see Matsuda, T. (200) 299
Baldwin, R., see Innis, R. (200) 369
Bao, G., Qadri, F., Stauss, B., Stauss, H., Gohlke, P. and Unger, T.
HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats (200) 179
Barnes, N.M., Cheng, C.H.K., Costall, B., Naylor, R.J., Williams, T.J. and Wischik, C.M.
Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease (200) 289
Barnes, P.J., see Lötvall, J.O. (200) 211
Baron, J.-C., see Petit-Taboué, M.-C. (200) 347
Barré, L., see Petit-Taboué, M.-C. (200) 347
Baumlin, Y., see Quast, U. (200) 239
Benloucif, S. and Galloway, M.P.
Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis (200) 1
Boldry, R.C., see Engber, T.M. (200) 171
Boniotti, A., see Mapp, C.E. (200) 73
Bray, K. and Quast, U.
Tedisamil (KC 8857) differentially inhibits the $^{86}Rb^{+}$ efflux-stimulating and vasorelaxant properties of cromakalim (200) 163
Brime, J., see Lopez-Sela, P. (200) 125
Britton, D.R., Kebabian, J.W. and Curzon, P.
Rapid reversal of denervation supersensitivity of dopamine D_1 receptors by l-dopa or a novel dopamine D_1 receptor agonist, A68930 (200) 89
Broadley, K.J., see Urquhart, R.A. (200) 35
Brooks, D.P. and Weinstock, J.
The pharmacology of pramipexole in the spontaneously hypertensive rat (200) 339
Brouwer, F., see Hollenga, C. (200) 325
Bruhwyler, J., Chleide, E., Houbeau, G. and Mercier, M.
Stimulant effect of the β-carboline FG 7142 in the open-field test (200) 183
Brunelle, G., see Junien, J.L. (200) 343
Brunner, F., Kühberger, E., Groschner, K., Pöch, G. and Kukovetz, W.R.
Characterization of muscarinic receptors mediating endothelium-dependent relaxation of bovine coronary artery (200) 25
Buchheit, K.-H., Gamse, R. and Pfannkuche, H.-J.
SDZ 205-557, a selective antagonist at 5-HT_4 receptors in the isolated guinea pig ileum (200) 373
Buchholz, R.A., see Dundore, R.L. (200) 83
Buckett, W.R., see Martin, K.F. (200) 191
Bult, H., see Jorens, P.G. (200) 205
Burks, T.F., see Slaninova, J. (200) 195

Camsonne, R., see Petit-Taboué, M.-C. (200) 347
Carboni, S., see Rossetti, Z.L. (200) 371
Carter, A.J. and Müller, R.E.
Pramipexole, a dopamine D_2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo (200) 65
Charney, D., see Innis, R. (200) 369
Chase, T.N., see Engber, T.M. (200) 171
Chen, K.-M., see Guan, Y.-Y. (200) 283
Cheng, C.H.K., see Barnes, N.M. (200) 289
Chitano, P., see Mapp, C.E. (200) 73
Chleide, E., see Bruhwyler, J. (200) 183
Chung, K.F., see Lötvall, J.O. (200) 211
Conarty, P.F., see Johnson, M.P. (200) 9
Costales, M., see Lopez-Sela, P. (200) 125
Costall, B., see Barnes, N.M. (200) 289
Cragoe, Jr., E.J., see Garay, R.P. (200) 141
Curzon, P., see Britton, D.R. (200) 89
Czuczwar, S.J., see Urbańska, E. (200) 277

Demichel, P., see Roquebert, J. (200) 59
Díaz, F., see Lopez-Sela, P. (200) 125
Diehl, J., see Kraft, K. (200) 219
Diener, M., Eglème, C. and Rummel, W.
Phospholipase C-induced anion secretion and its interaction with carbachol in the rat colonic mucosa (200) 267
Dundore, R.L., Pratt, P.F., O'Connor, B., Buchholz, R.A. and Pagani, E.D.
N^{ω}-Nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast (200) 83
Dziki, M., see Urbańska, E. (200) 277

Egen, A., see Kraft, K. (200) 219
Eglème, C., see Diener, M. (200) 267
Endoh, M., see Ishihata, A. (200) 199
Engber, T.M., Boldry, R.C. and Chase, T.N.
The κ-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D_1 and D_2 agonists (200) 171

Fabbri, L.M., see Mapp, C.E. (200) 73
Fang, S.-N., see Slaninova, J. (200) 195
Fleming, I., Gray, G.A., Schott, C. and Stoclet, J.-C.
Inducible but not constitutive production of nitric oxide by vascular smooth muscle cells (200) 375
Forster, C., Wanes, D. and Armstrong, P.W.
Novel vascular effects of isoprenaline following pacing-induced heart failure in the dog (200) 251
Förstermann, U., see Kuhn, M. (200) 175
Fowler, L.J., see Whitton, P.S. (200) 167
Frölich, J.C., see Kuhn, M. (200) 175
Furuya, M., Ohnuma, N., Takehisa, M., Hayashi, Y., Ishihara, T., Minamino, N., Kangawa, K. and Matsuo, H.
Pharmacological activities of brain natriuretic peptides of human, porcine and rat origin (200) 233

Gall, D.G., see MacNaughton, W.K. (200) 17
Galloway, M.P., see Benloucif, S. (200) 1
Gamse, R., see Buchheit, K.-H. (200) 373

Garay, R.P., Nazaret, C. and Cragoe, Jr., E.J.
Evidence for the O-sulfo derivative of MK-447 as active metabolite of MK-447 (200) 141
Garratt, J.C., see Kidd, E.J. (200) 131
Gessa, G.L., see Rossetti, Z.L. (200) 371
Glenert, U.
In vitro methods for the assessment of the inhibitory effects of antidepressants in rat parotid glands (200) 113
Gohlke, P., see Bao, G. (200) 179
Gonzalvez, M.L., Milanés, M.V. and Vargas, M.L.
Effects of acute and chronic administration of μ- and δ-opioid agonists on the hypothalamic–pituitary–adrenocortical (HPA) axis in the rat (200) 155
Graf, P.D., see Mapp, C.E. (200) 73
Gray, G.A., see Fleming, I. (200) 375
Gregersen, H., Jensen, S.L. and Ahrén, B.
An α_1-adrenoceptor-sensitive mechanism is responsible for the adrenergic inhibition of insulin secretion in the pig pancreas (200) 365
Groschner, K., see Brunner, F. (200) 25
Guan, Y.-Y., Chen, K.-M. and Sun, J.-J.
α_1-Adrenoceptors mediate the responses to BHT-920 and rauwolscine in dog mesenteric artery after partial depolarization by KCl (200) 283

Hayashi, Y., see Furuya, M. (200) 233
Herchuelz, A., see Lebrun, P. (200) 159
Herman, A.G., see Jorens, P.G. (200) 205
Hermann, M., see Lebrun, P. (200) 159
Herz, A., see Spanagel, R. (200) 319
Hoffer, P., see Innis, R. (200) 369
Hollenga, C., Brouwer, F. and Zaagsma, J.
Differences in functional cyclic AMP compartments mediating lipolysis by isoprenaline and BRL 37344 in four adipocyte types (200) 325
Houbeau, G., see Bruhwyler, J. (200) 183
Hruby, V.J., see Slaninova, J. (200) 195
Huang, X., Johnson, M.P. and Nichols, D.E.
Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (200) 187

Ikebuchi, M., see Tanaka, Y. (200) 353
Ikegami, A., see Ozaki, A. (200) 311
Inazu, M., see Sakai, Y. (200) 227
Innis, R., Baldwin, R., Sybirska, E., Zea, Y., Laruelle, M., Al-Tikriti, M., Charney, D., Zoghbi, S., Smith, E., Wisniewski, G., Hoffer, P., Wang, S., Milius, R. and Neumeyer, J.
Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [^{123}I]CIT (200) 369
Insel, T.R., see Winslow, J. (200) 95
Ishihara, T., see Furuya, M. (200) 233
Ishihata, A., Katano, Y., Morinobu, S. and Endoh, M.
Influence of aging on the contractile response to endothelin of rat thoracic aorta (200) 199
Iwata, H., see Matsuda, T. (200) 299

Jensen, S.L., see Gregersen, H. (200) 365
Johnson, M.P., Conarty, P.F. and Nichols, D.E.
[^{3}H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues (200) 9
Johnson, M.P., see Huang, X. (200) 187
Jorens, P.G., Van Overveld, F.J., Bult, H., Vermeire, P.A. and Herman, A.G.
L-Arginine-dependent production of nitrogen oxides by rat pulmonary macrophages (200) 205
Junien, J.L., Roman, F.J., Brunelle, G. and Pascaud, X.
JO1784, a novel σ ligand, potentiates [^{3}H]acetylcholine release from rat hippocampal slices (200) 343

Kanda, T., see Matsuda, T. (200) 299
Kaneto, H., see Takahashi, M. (200) 293
Kangawa, K., see Furuya, M. (200) 233
Kashiwagi, A., see Tanaka, Y. (200) 353
Katano, Y., see Ishihata, A. (200) 199
Kebabian, J.W., see Britton, D.R. (200) 89
Kellett, R., see Martin, K.F. (200) 191
Kidd, E.J., Garratt, J.C. and Marsden, C.A.
Effects of repeated treatment with 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on the autoregulatory control of dorsal raphe 5-HT neuronal firing and cortical 5-HT release (200) 131
King, K.A. and McCall, R.B.
The effects of 8-OH-DPAT on medullary 5-HT neurons and sympathetic activity in baroreceptor-denervated animals (200) 357
Kleinrok, Z., see Urbańska, E. (200) 277
Knapp, R.J., see Slaninova, J. (200) 195
Kraft, K., Diehl, J., Egen, A. and Stumpe, K.-O.
Chronic κ-opioid receptor antagonism delays the rise in blood pressure in spontaneously hypertensive rats (200) 219
Kramer, T., see Slaninova, J. (200) 195
Kühberger, E., see Brunner, F. (200) 25
Kuhn, M., Otten, A., Frölich, J.C. and Förstermann, U.
Glyceryl trinitrate increases platelet cyclic GMP after metabolism in fibroblasts (200) 175
Kukovetz, W.R., see Brunner, F. (200) 25

Larsson, K., see Ahlenius, S. (200) 259
Laruelle, M., see Innis, R. (200) 369
Lebrun, P., Antoine, M.-H., Hermann, M. and Herchuelz, A.
RP 49356: inhibitory effects of ionic and secretory events in rat pancreatic islets (200) 159
Lefebvre, R.A., see Smits, G.J. (200) 361
Lin, Y. and Phillis, J.W.
Muscarinic receptor agonist-mediated modulation of neuronal activity in rat cerebral cortex (200) 45
Lopez-Sela, P., Brime, J., Díaz, F., Marín, B., Costales, M. and Vijande, M.
Attenuation of insulin-induced drinking by β-adrenoceptor antagonists (200) 125
Lötvall, J.O., Tokuyama, K., Barnes, P.J. and Chung, K.F.
Bradykinin-induced airway microvascular leakage is potentiated by captopril and phosphoramidon (200) 211

MacKenzie, E.T., see Petit-Taboué, M.-C. (200) 347
MacNaughton, W.K. and Gall, D.G.
Mechanisms of platelet-activating factor-induced electrolyte transport in the rat jejunum (200) 17
Mapp, C.E., Boniotti, A., Graf, P.D., Chitano, P., Fabbri, L.M. and Nadel, J.A.
Bronchial smooth muscle responses evoked by toluene diisocyanate are inhibited by ruthenium red and by indomethacin (200) 73
Marín, B., see Lopez-Sela, P. (200) 125
Marsden, C.A., see Kidd, E.J. (200) 131
Martin, K.F., Kellett, R. and Buckett, W.R.
Membrane stabilising properties of the selective 5-HT$_2$ receptor agonist, (±)-DOI (200) 191
Maslowski, R.J. and Napier, T.C.
Dopamine D$_1$ and D$_2$ receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons (200) 103
Matsuda, T., Nakano, Y., Kanda, T., Iwata, H. and Baba, A.
Gonadectomy changes the pituitary-adrenocortical response in mice to 5-HT$_{1A}$ receptor agonists (200) 299

Matsuo, H., see Furuya, M. (200) 233
McCall, R.B., see King, K.A. (200) 357
Melchers, B.P.C., Van der Laaken, A.L. and Van Helden, H.P.M.
On the mechanism whereby HI-6 improves neuromuscular function after oxime-resistant acetylcholinesterase inhibition and subsequent impairment of neuromuscular transmission (200) 331
Melis, F., see Rossetti, Z.L. (200) 371
Mercier, M., see Bruhwyler, J. (200) 183
Milanés, M.V., see Gonzalvez, M.L. (200) 155
Milius, R., see Innis, R. (200) 369
Minamino, N., see Furuya, M. (200) 233
Moran, A., see Roquebert, J. (200) 59
Morinobu, S., see Ishihata, A. (200) 199
Müller, R.E., see Carter, A.J. (200) 65

Nadel, J.A., see Mapp, C.E. (200) 73
Nakano, Y., see Matsuda, T. (200) 299
Napier, T.C., see Maslowski, R.J. (200) 103
Nash, J.F. and Nichols, D.E.
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues (200) 53
Naylor, R.J., see Barnes, N.M. (200) 289
Nazaret, C., see Garay, R.P. (200) 141
Neumeyer, J., see Innis, R. (200) 369
Nichols, D.E., see Huang, X. (200) 187
Nichols, D.E., see Johnson, M.P. (200) 9
Nichols, D.E., see Nash, J.F. (200) 53
Nomura, Y., see Tohda, M. (200) 305

O'Connor, B., see Dundore, R.L. (200) 83
Ogawa, N., see Yoshimura, H. (200) 147
Ogawa, T., see Tanaka, Y. (200) 353
Ohnuma, N., see Furuya, M. (200) 233
Otten, A., see Kuhn, M. (200) 175
Ozaki, A., Ikegami, A., Yoshidomi, M., Yamashita, A. and Sukamoto, T.
Behavioral and biochemical effects of a novel calcium antagonist, KB-2796, on the central dopaminergic system (200) 311

Pagani, E.D., see Dundore, R.L. (200) 83
Pang, C.C.Y., see Wang, Y.-X. (200) 77
Pascaud, X., see Junien, J.L. (200) 343
Petit-Taboué, M.-C., Baron, J.-C., Barré, L., Travère, J.-M., Speckel, D., Camsonne, R. and MacKenzie, E.T.
Brain kinetics and specific binding of [^{11}C]PK 11195 to ω_3 sites in baboons: positron emission tomography study (200) 347
Pfannkuche, H.-J., see Buchheit, K.-H. (200) 373
Phillis, J.W., see Lin, Y. (200) 45
Pöch, G., see Brunner, F. (200) 25
Pratt, P.F., see Dundore, R.L. (200) 83

Qadri, F., see Bao, G. (200) 179
Quast, U. and Baumlin, Y.
Cromakalim inhibits contractions of the rat isolated mesenteric bed induced by noradrenaline but not caffeine in Ca^{2+}-free medium: evidence for interference with receptor-mediated Ca^{2+} mobilization (200) 239
Quast, U., see Bray, K. (200) 163

Roman, F.J., see Junien, J.L. (200) 343
Roquebert, J., Moran, A., Demichel, P. and Sauvage, M.-F.
Pharmacological characterization of dopamine receptors in parasympathetic innervation of rat heart (200) 59
Rossetti, Z.L., Melis, F., Carboni, S. and Gessa, G.L.
Marked decrease of extraneuronal dopamine after alcohol withdrawal in rats: reversal by *MK*-801 (200) 371
Rummel, W., see Diener, M. (200) 267

Sakai, Y. and Inazu, M.
Sodium pump activity and contraction of renal artery from spontaneously hypertensive rats (200) 227
Sauvage, M.-F., see Roquebert, J. (200) 59
Schott, C., see Fleming, I. (200) 375
Senda, T., see Takahashi, M. (200) 293
Shigeta, Y., see Tanaka, Y. (200) 353
Shippenberg, T.S., see Spanagel, R. (200) 319
Slaninova, J., Knapp, R.J., Wu, J., Fang, S.-N., Kramer, T., Burks, T.F., Hruby, V.J. and Yamamura, H.I.
Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide (200) 195
Smith, E., see Innis, R. (200) 369
Smits, G.J. and Lefebvre, R.A.
Influence of thiorphan and phosphoramidon on the relaxant effect of vasoactive intestinal polypeptide and non-adrenergic non-cholinergic neurone stimulation in the rat gastric fundus (200) 361
Spanagel, R., Herz, A. and Shippenberg, T.S.
Modulation of the mesolimbic dopaminergic system by β-endorphin-(1-27) as assessed by microdialysis (200) 319
Speckel, D., see Petit-Taboué, M.-C. (200) 347
Stauss, B., see Bao, G. (200) 179
Stauss, H., see Bao, G. (200) 179
Stoclet, J.-C., see Fleming, I. (200) 375
Stumpe, K.-O., see Kraft, K. (200) 219
Sukamoto, T., see Ozaki, A. (200) 311
Sun, J.-J., see Guan, Y.-Y. (200) 283
Sybirska, E., see Innis, R. (200) 369

Takagi, Y., see Tanaka, Y. (200) 353
Takahashi, M., Senda, T. and Kaneto, H.
Role of spinal κ opioid receptors in the blockade of the development of antinociceptive tolerance to morphine (200) 293
Takehisa, M., see Furuya, M. (200) 233
Tanaka, Y., Kashiwagi, A., Ogawa, T., Abe, N., Asahina, T., Ikebuchi, M., Takagi, Y. and Shigeta, Y.
Effect of verapamil on cardiac protein kinase C activity in diabetic rats (200) 353
Tohda, M. and Nomura, Y.
Biphasic effects of mianserin and desipramine on serotonin-evoked current and Cl^- efflux in *Xenopus* oocytes (200) 305
Tokuyama, K., see Lötvall, J.O. (200) 211
Travère, J.-M., see Petit-Taboué, M.-C. (200) 347
Turski, W.A., see Urbańska, E. (200) 277

Unger, T., see Bao, G. (200) 179
Urbańska, E., Dziki, M., Kleinrok, Z., Czuczwar, S.J. and Turski, W.A.
Influence of MK-801 on the anticonvulsant activity of antiepileptics (200) 277
Urquhart, R.A. and Broadley, K.J.
Comparison of adenosine receptor agonists with other vasodilators on noradrenaline-, potassium- and phorbol ester-contracted rabbit aorta (200) 35

Van der Laaken, A.L., see Melchers, B.P.C. (200) 331
Van Helden, H.P.M., see Melchers, B.P.C. (200) 331
Van Overveld, F.J., see Jorens, P.G. (200) 205
Vargas, M.L., see Gonzalvez, M.L. (200) 155
Vermeire, P.A., see Jorens, P.G. (200) 205
Vijande, M., see Lopez-Sela, P. (200) 125

Wanes, D., see Forster, C. (200) 251
Wang, S., see Innis, R. (200) 369
Wang, Y.-X., Zhou, T. and Pang, C.C.Y.
Pressor effects of L and D enantiomers of N^G-nitro-arginine in conscious rats are antagonized by L- but not D-arginine (200) 77

Weinstock, J., see Brooks, D.P. (200) 339
Whitton, P.S. and Fowler, L.J.
The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo (200) 167
Wijkström, A., see Ahlenius, S. (200) 259
Williams, T.J., see Barnes, N.M. (200) 289
Winslow, J. and Insel, T.R.
Vasopressin modulates male squirrel monkeys' behavior during social separation (200) 95
Wischik, C.M., see Barnes, N.M. (200) 289
Wisniewski, G., see Innis, R. (200) 369
Wu, J., see Slaninova, J. (200) 195
Yamamura, H.I., see Slaninova, J. (200) 195
Yamashita, A., see Ozaki, A. (200) 311
Yoshidomi, M., see Ozaki, A. (200) 311
Yoshimura, H. and Ogawa, N.
Ethopharmacology of maternal aggression in mice: effects of diazepam and SM-3997 (200) 147

Zaagsma, J., see Hollenga, C. (200) 325
Zea, Y., see Innis, R. (200) 369
Zhou, T., see Wang, Y.-X. (200) 77
Zoghbi, S., see Innis, R. (200) 369

European Journal of Pharmacology, 200 (1991) 385–393
© 1991 Elsevier Science Publishers B.V. 0014-2999/91/$03.50

Key word index

A-68930
Dopamine D_1 receptors; Dopamine; Denervation supersensitivity; Rotation; Locomotion; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Acetylcholine
Aging; Endothelin-1; Aorta (rat) (Ishihata, A. (200) 199)

Acetylcholine release
JO1784; Di-o-tolyl-guanidine; (+)-SKF 10,047; Hippocampus (rat); σ Receptors; Phencyclidine (Junien, J.L. (200) 343)

Acetylcholinesterase inhibition
HI-6; Neuromuscular junction; Electrophysiology; Muscle contractions; Organophosphate; (Direct effect) (Melchers, B.P.C. (200) 331)

Adenosine
Aorta (rabbit); Ca^{2+} channels (receptor-operated); Ca^{2+} channels (voltage-operated); Phorbol dibutyrate (Urquhart, R.A. (200) 35)

Adipocytes
cAMP; Lipolysis; β_3-Adrenoceptors (atypical) (Hollenga, C. (200) 325)

α-Adrenoceptors
Ca^{2+} influx; Smooth muscle (vascular); Mesenteric artery (Guan, Y.-Y. (200) 283)

Dopamine receptors; Spontaneously hypertensive rat (SHR) (Brooks, D.P. (200) 339)

Insulin secretion; Noradrenaline; Prazosin; Idazoxan; Phenylephrine (Gregersen, H. (200) 365)

α_2-Adrenoceptors
Isoprenaline; Saphenous vein; Congestive heart failure (Forster, C. (200) 251)

β_3-Adrenoceptors (atypical)
cAMP; Lipolysis; Adipocytes (Hollenga, C. (200) 325)

Aging
Endothelin-1; Acetylcholine; Aorta (rat) (Ishihata, A. (200) 199)

Airflow obstruction
Airway secretion; Plasma exudation; Peptidases; (Guinea-pig) (Lötvall, J.O. (200) 211)

Airway secretion
Airflow obstruction; Plasma exudation; Peptidases; (Guinea-pig) (Lötvall, J.O. (200) 211)

Alveolar macrophages
Pleural macrophages; L-Arginine; Glucocorticoids; Nitric oxide (NO); Pulmonary; (Rat) (Jorens, P.G. (200) 205)

Alzheimer's disease
Angiotensin converting enzyme; Temporal cortex (human) (Barnes, N.M. (200) 289)

cAMP
Autonomic receptors; cGMP; Oxygen consumption; Parotid gland (rat); Antidepressants (Glenert, U. (200) 113)

Lipolysis; Adipocytes; β_3-Adrenoceptors (atypical) (Hollenga, C. (200) 325)

Analgesia
Cholecystokinin (CCK); CCK analogues; Opioid receptors; CCK-B receptors; Radioligand binding (Slaninova, J. (200) 195)

Analgesic tolerance
Morphine; U-50,488H; Spinal analgesia; κ Opioid receptors; Nor-binaltorphimine (Takahashi, M. (200) 293)

Angiotensin converting enzyme
Alzheimer's disease; Temporal cortex (human) (Barnes, N.M. (200) 289)

ANP (atrial natriuretic polypeptide)
BNP (brain natriuretic polypeptide); Diuresis; Vasorelaxation; cGMP; (Receptor) (Furuya, M. (200) 233)

Antidepressants
Autonomic receptors; cAMP; cGMP; Oxygen consumption; Parotid gland (rat) (Glenert, U. (200) 113)

5-HT (5-hydroxytryptamine, serotonin); $^{36}Cl^-$ efflux; Current responses; Brain mRNA; (*Xenopus* oocyte) (Tohda, M. (200) 305)

Antiepileptics
Electroshock (maximal); MK-801; Seizures (Urbańska, E. (200) 277)

Anxiety
FG 7142; Benzodiazepine inverse agonists; Anxiogenic activity; Open field; (Rat) (Bruhwyler, J. (200) 183)

Anxiogenic activity
FG 7142; Benzodiazepine inverse agonists; Open field; Anxiety; (Rat) (Bruhwyler, J. (200) 183)

Anxiolytics
Maternal aggression; Psychotropic action; Diazepam; SM-3997; (Female mouse) (Yoshimura, H. (200) 147)

Aorta (rabbit)
Adenosine; Ca^{2+} channels (receptor-operated); Ca^{2+} channels (voltage-operated); Phorbol dibutyrate (Urquhart, R.A. (200) 35)

Aorta (rat)
K^+ channel blockers; Tedisamil; Glibenclamide; K^+ channel openers; Cromakalim (Bray, K. (200) 163)

Aging; Endothelin-1; Acetylcholine (Ishihata, A. (200) 199)

Arachidonic acid
Cl^- secretion; Prostaglandins; Intestinal transport (MacNaughton, W.K. (200) 17)

D-Arginine
N^G-Nitro-L-arginine; N^G-Nitro-D-arginine; L-Arginine; Pressor effects (Wang, Y.-X. (200) 77)

L-Arginine
N^G-Nitro-L-arginine; N^G-Nitro-D-arginine; D-Arginine; Pressor effects (Wang, Y.-X. (200) 77)

Alveolar macrophages; Pleural macrophages; Glucocorticoids; Nitric oxide (NO); Pulmonary; (Rat) (Jorens, P.G. (200) 205)

Asthma
Toluene diisocyanate; Sensory nerves; Prostaglandins (Mapp, C.E. (200) 73)

Atenolol
Insulin-induced drinking; Water intake; Propranolol; Butoxamine; Phenoxybenzamine (Lopez-Sela, P. (200) 125)

Autonomic receptors
cAMP; cGMP; Oxygen consumption; Parotid gland (rat); Antidepressants (Glenert, U. (200) 113)

Behaviour
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Ahlenius, S. (200) 259)

Benzodiazepine inverse agonists
FG 7142; Anxiogenic activity; Open field; Anxiety; (Rat) (Bruhwyler, J. (200) 183)

Binding (in vivo)
Peripheral-type benzodiazepine binding sites; [^{11}C]PK 11195; PET (positron emission tomography) (Petit-Taboué, M.-C. (200) 347)

Blood pressure
EDRF (endothelium-derived relaxing factor); cGMP; Phosphodiesterase inhibitors; Zaprinast; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (200) 83)

BNP (brain natriuretic polypeptide)
ANP (atrial natriuretic polypeptide); Diuresis; Vasorelaxation; cGMP; (Receptor) (Furuya, M. (200) 233)

Bradykinin
Bradykinin antagonists; Plasma catecholamines; (Conscious rat) (Bao, G. (200) 179)

Bradykinin antagonists
Bradykinin; Plasma catecholamines; (Conscious rat) (Bao, G. (200) 179)

Brain mRNA
5-HT (5-hydroxytryptamine, serotonin); Antidepressants; $^{36}Cl^-$ efflux; Current responses; (*Xenopus* oocyte) (Tohda, M. (200) 305)

Butoxamine
Insulin-induced drinking; Water intake; Propranolol; Atenolol; Phenoxybenzamine (Lopez-Sela, P. (200) 125)

Ca^{2+}
Phospholipase C; Cl^- secretion; Protein kinase C (Diener, M. (200) 267)

Ca^{2+} channel antagonists
KB-2796; Dopamine; Stereotypy; Monoamine content; Dopamine turnover (Ozaki, A. (200) 311)

Ca^{2+} channels (receptor-operated)
Adenosine; Aorta (rabbit); Ca^{2+} channels (voltage-operated); Phorbol dibutyrate (Urquhart, R.A. (200) 35)

Ca^{2+} channels (voltage-operated)
Adenosine; Aorta (rabbit); Ca^{2+} channels (receptor-operated); Phorbol dibutyrate (Urquhart, R.A. (200) 35)

Caffeine
Cromakalim (BRL 34915); K^+ channel openers; Ryanodine; Ca^{2+} (mobilization of intracellular); Mesenteric resistance vessels (rat) (Quast, U. (200) 239)

Ca^{2+} influx
α-Adrenoceptors; Smooth muscle (vascular); Mesenteric artery (Guan, Y.-Y. (200) 283)

Ca^{2+} (mobilization of intracellular)
Cromakalim (BRL 34915); K^+ channel openers; Caffeine; Ryanodine; Mesenteric resistance vessels (rat) (Quast, U. (200) 239)

Cardiac protein kinase C
Verapamil; Diabetes; (Rat) (Tanaka, Y. (200) 353)

CCK analogues
Cholecystokinin (CCK); Opioid receptors; CCK-B receptors; Radioligand binding; Analgesia (Slaninova, J. (200) 195)

CCK-B receptors
Cholecystokinin (CCK); CCK analogues; Opioid receptors; Radioligand binding; Analgesia (Slaninova, J. (200) 195)

Cell membranes
Sulfates; Ion transport; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Cerebral cortex
Muscarinic receptor agonists; Muscarinic receptor antagonists; Neuronal activity; (Modulation); (Rat) (Lin, Y. (200) 45)

p-Chloroamphetamine (PCA)
α-Ethyltryptamine (Monase); 5-HT neurotoxicity; MDMA (3,4-methylenedioxymethamphetamine) (Huang, X. (200) 187)

Cholecystokinin (CCK)
CCK analogues; Opioid receptors; CCK-B receptors; Radioligand binding; Analgesia (Slaninova, J. (200) 195)

Cholinergic vasodilatation
Muscarinic receptors; Vascular endothelium; Coronary artery (bovine); (Functional experiments in vitro) (Brunner, F. (200) 25)

$^{36}Cl^-$ efflux
5-HT (5-hydroxytryptamine, serotonin); Antidepressants; Current responses; Brain mRNA; (*Xenopus* oocyte) (Tohda, M. (200) 305)

Cl^- secretion
Arachidonic acid; Prostaglandins; Intestinal transport (MacNaughton, W.K. (200) 17)

Phospholipase C; Ca^{2+}; Protein kinase C (Diener, M. (200) 267)

Cl^- transport
Sulfates; Cell membranes; Ion transport; Na^+ transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Congestive heart failure
Isoprenaline; Saphenous vein; α_2-Adrenoceptors (Forster, C. (200) 251)

Contraction
Na^+ pump; Renal artery; Spontaneously hypertensive rat (SHR) (Sakai, Y. (200) 227)

Coronary artery (bovine)
Muscarinic receptors; Vascular endothelium; Cholinergic vasodilatation; (Functional experiments in vitro) (Brunner, F. (200) 25)

Corticosterone
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sex differences; Estradiol (Matsuda, T. (200) 299)

m-CPP (1-(m-chlorophenyl)piperazine)
Dopamine release; 5-HT receptor agonists; Microdialysis; TFMPP (trifluoromethylphenylpiperazine) (Facilitation) (Benloucif, S. (200) 1)

Cromakalim
K^+ channel blockers; Tedisamil; Glibenclamide; K^+ channel openers; Aorta (rat) (Bray, K. (200) 163)

Cromakalim (BRL 34915)
K^+ channel openers; Caffeine; Ryanodine; Ca^{2+} (mobilization of intracellular); Mesenteric resistance vessels (rat) (Quast, U. (200) 239)

Current responses
5-HT (5-hydroxytryptamine, serotonin); Antidepressants; $^{36}Cl^-$ efflux; Brain mRNA; (*Xenopus* oocyte) (Tohda, M. (200) 305)

DAGO ([D-Ala^2,N-MePhe^4,Gly-ol^5]enkephalin)
μ-Opioid receptors; δ-Opioid receptors; Hypothalimic–pituitary–adrenocortical (HPA) axis; DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Gonzalvez, M.L. (200) 155)

Denervation supersensitivity
Dopamine D_1 receptors; Dopamine; Rotation; Locomotion; A-68930; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Diabetes
Verapamil; Cardiac protein kinase C; (Rat) (Tanaka, Y. (200) 353)

Diazepam
Maternal aggression; Psychotropic action; SM-3997; Anxiolytics; (Female mouse) (Yoshimura, H. (200) 147)

Di-o-tolyl-guanidine
JO1784; (+)-SKF 10,047; Hippocampus (rat); Acetylcholine release; σ Receptors; Phencyclidine (Junien, J.L. (200) 343)

Diuresis
BNP (brain natriuretic polypeptide); ANP (atrial natriuretic polypeptide); Vasorelaxation; cGMP; (Receptor) (Furuya, M. (200) 233)

Diuretics
Sulfates; Cell membranes; Ion transport; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
5-HT release in vivo; Dorsal raphe nucleus; 5-HT neuronal firing; 5-HT_2 /5-HT_{1A} receptor interaction (Kidd, E.J. (200) 131)

Membrane stabilisation; Sciatic nerve (frog) (Martin, K.F. (200) 191)

l-DOPA (l-dihydroxyphenylalanine)
Dopamine D_1 receptors; Dopamine; Denervation supersensitivity; Rotation; Locomotion; A-68930; SK&F 38393 (Britton, D.R. (200) 89)

Dopamine
5-HT (5-hydroxytryptamine, serotonin); Microdialysis (in vivo); MDA (methylenedioxyamphetamine); MDMA (3,4-methylenedioxymethamphetamine); Neurotoxicity (Nash, J.F. (200) 53)

Microdialysis; Dopamine D_2 receptors; Pramipexole (SND 919); Talipexole (B-HT 920); Sulpiride; SCH 23390; Striatum (Carter, A.J. (200) 65)

Dopamine D_1 receptors; Denervation supersensitivity; Rotation; Locomotion; A-68930; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Ventral pallidum; Substantia innominata; Dopamine D_1 receptors; Dopamine D_2 receptors; Single neuron recordings (extracellular) (Maslowski, R.J. (200) 103)

KB-2796; Ca^{2+} channel antagonists; Stereotypy; Monoamine content; Dopamine turnover (Ozaki, A. (200) 311)

[^{3}H]Dopamine
[^{3}H]5-HT; [^{3}H]Norepinephrine; Uptake inhibition; Non-vesicular release; MDMA (3,4-methylenedioxymethamphetamine) (Johnson, M.P. (200) 9)

Dopamine receptor agonists
Parasympathetic control; Dopaminergic control; Vagal bradycardia; Dopamine receptors (Roquebert, J. (200) 59)

Dopamine receptors
Parasympathetic control; Dopaminergic control; Vagal bradycardia; Dopamine receptor agonists (Roquebert, J. (200) 59)

α-Adrenoceptors; Spontaneously hypertensive rat (SHR) (Brooks, D.P. (200) 339)

Dopamine D_1 receptors
Dopamine; Denervation supersensitivity; Rotation; Locomotion; A-68930; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Dopamine; Ventral pallidum; Substantia innominata; Dopamine D_2 receptors; Single neuron recordings (extracellular) (Maslowski, R.J. (200) 103)

Dopamine D_2 receptors
Dopamine; Microdialysis; Pramipexole (SND 919); Talipexole (B-HT 920); Sulpiride; SCH 23390; Striatum (Carter, A.J. (200) 65)

Dopamine; Ventral pallidum; Substantia innominata; Dopamine D_1 receptors; Single neuron recordings (extracellular) (Maslowski, R.J. (200) 103)

Dopamine release
5-HT receptor agonists; Microdialysis; m-CPP (1-(m-chlorophenyl)-piperazine); TFMPP (trifluoromethylphenylpiperazine) (Facilitation) (Benloucif, S. (200) 1)

Dopamine release/overflow
Microdialysis; β-Endorphin-(1-27); Nucleus accumbens; (Intracerebroventricular); (Rat) (Spanagel, R. (200) 319)

Dopaminergic control
Parasympathetic control; Vagal bradycardia; Dopamine receptors; Dopamine receptor agonists (Roquebert, J. (200) 59)

Dopamine turnover
KB-2796; Ca^{2+} channel antagonists; Dopamine; Stereotypy; Monoamine content (Ozaki, A. (200) 311)

Dorsal raphe nucleus
5-HT release in vivo; 5-HT neuronal firing; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2/5-HT_{1A} receptor interaction (Kidd, E.J. (200) 131)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
μ-Opioid receptors; δ-Opioid receptors; Hypothalimic–pituitary–adrenocortical (HPA) axis; DAGO ([D-Ala^2,N-MePhe^4,Gly-ol^5]enkephalin) (Gonzalvez, M.L. (200) 155)

EDRF (endothelium-derived relaxing factor)
cGMP; Phosphodiesterase inhibitors; Zaprinast; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (200) 83)

Nitric oxide (NO); cGMP; Platelets; Endothelial cells (cultured); Fibroblasts (RFL-6 cells) (Kuhn, M. (200) 175)

Electrophysiology
HI-6; Acetylcholinesterase inhibition; Neuromuscular junction; Muscle contractions; Organophosphate; (Direct effect) (Melchers, B.P.C. (200) 331)

Electroshock (maximal)
MK-801; Antiepileptics; Seizures (Urbańska, E. (200) 277)

β-Endorphin-(1-27)
Dopamine release/overflow; Microdialysis; Nucleus accumbens; (Intracerebroventricular); (Rat) (Spanagel, R. (200) 319)

Endothelial cells (cultured)
Nitric oxide (NO); cGMP; Platelets; Fibroblasts (RFL-6 cells); EDRF (endothelium-derived relaxing factor) (Kuhn, M. (200) 175)

Endothelin-1
Aging; Acetylcholine; Aorta (rat) (Ishihata, A. (200) 199)

Estradiol
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Corticosterone; Sex differences (Matsuda, T. (200) 299)

α-Ethyltryptamine (Monase)
5-HT neurotoxicity; MDMA (3,4-methylenedioxymethamphetamine); p-Chloroamphetamine (PCA) (Huang, X. (200) 187)

FG 7142
Benzodiazepine inverse agonists; Anxiogenic activity; Open field; Anxiety; (Rat) (Bruhwyler, J. (200) 183)

Fibroblasts (RFL-6 cells)
Nitric oxide (NO); cGMP; Platelets; Endothelial cells (cultured); EDRF (endothelium-derived relaxing factor) (Kuhn, M. (200) 175)

Flesinoxan
Behaviour; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Ahlenius, S. (200) 259)

Gastric fundus (rat)
Non-adrenergic, non-cholinergic (NANC) neurotransmitters; VIP (vasoactive intestinal peptide); Neutral endopeptidase; Thiorphan; Phosphoramidon (Smits, G.J. (200) 361)

Glibenclamide
K^+ channel blockers; Tedisamil; K^+ channel openers; Cromakalim; Aorta (rat) (Bray, K. (200) 163)

Glucocorticoids
Alveolar macrophages; Pleural macrophages; L-Arginine; Nitric oxide (NO); Pulmonary; (Rat) (Jorens, P.G. (200) 205)

cGMP
EDRF (endothelium-derived relaxing factor); Phosphodiesterase inhibitors; Zaprinast; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (200) 83)

Autonomic receptors; cAMP; Oxygen consumption; Parotid gland (rat); Antidepressants (Glenert, U. (200) 113)

Nitric oxide (NO); Platelets; Endothelial cells (cultured); Fibroblasts (RFL-6 cells); EDRF (endothelium-derived relaxing factor) (Kuhn, M. (200) 175)

BNP (brain natriuretic polypeptide); ANP (atrial natriuretic polypeptide); Diuresis; Vasorelaxation; (Receptor) (Furuya, M. (200) 233)

HI-6
Acetylcholinesterase inhibition; Neuromuscular junction; Electrophysiology; Muscle contractions; Organophosphate; (Direct effect) (Melchers, B.P.C. (200) 331)

Hippocampus (rat)
JO1784; Di-o-tolyl-guanidine; (+)-SKF 10,047; Acetylcholine release; σ Receptors; Phencyclidine (Junien, J.L. (200) 343)

[^{3}H]5-HT
[^{3}H]Dopamine; [^{3}H]Norepinephrine; Uptake inhibition; Non-vesicular release; MDMA (3,4-methylenedioxymethamphetamine) (Johnson, M.P. (200) 9)

5-HT (5-hydroxytryptamine, serotonin)
Dopamine; Microdialysis (in vivo); MDA (methylenedioxyamphetamine); MDMA (3,4-methylenedioxymethamphetamine); Neurotoxicity (Nash, J.F. (200) 53)

Valproate; Microdialysis (Whitton, P.S. (200) 167)

Behaviour; 5-HT_{1A} receptors; Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Ahlenius, S. (200) 259)

Antidepressants; $^{36}Cl^-$ efflux; Current responses; Brain mRNA; (*Xenopus* oocyte) (Tohda, M. (200) 305)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sympathetic activity; Unit activity (King, K.A. (200) 357)

5-HT neuronal firing
5-HT release in vivo; Dorsal raphe nucleus; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2/5-HT_{1A} receptor interaction (Kidd, E.J. (200) 131)

5-HT neurotoxicity
α-Ethyltryptamine (Monase); MDMA (3,4-methylenedioxymethamphetamine); p-Chloroamphetamine (PCA) (Huang, X. (200) 187)

5-HT receptor agonists
Dopamine release; Microdialysis; m-CPP (1-(m-chlorophenyl)piperazine); TFMPP (trifluoromethylphenylpiperazine) (Facilitation) (Benloucif, S. (200) 1)

5-HT_2 /5-HT_{1A} receptor interaction
5-HT release in vivo; Dorsal raphe nucleus; 5-HT neuronal firing; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Kidd, E.J. (200) 131)

5-HT_{1A} receptors
Behaviour; 5-HT (5-hydroxytryptamine, serotonin); Flesinoxan; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); (Rat) (Ahlenius, S. (200) 259)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Corticosterone; Sex differences; Estradiol (Matsuda, T. (200) 299)

5-HT release in vivo
Dorsal raphe nucleus; 5-HT neuronal firing; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_2 /5-HT_{1A} receptor interaction (Kidd, E.J. (200) 131)

Hypertension
MR-2266; MR-1452; Morphiceptin; MR-2033; κ-Opioid receptor antagonism (Kraft, K. (200) 219)

Hypothalimic–pituitary–adrenocortical (HPA) axis
μ-Opioid receptors; δ-Opioid receptors; DAGO ([D-Ala^2,N-MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Gonzalvez, M.L. (200) 155)

Idazoxan
Insulin secretion; α-Adrenoceptors; Noradrenaline; Prazosin; Phenylephrine (Gregersen, H. (200) 365)

Insulin-induced drinking
Water intake; Propranolol; Atenolol; Butoxamine; Phenoxybenzamine (Lopez-Sela, P. (200) 125)

Insulin release
RP 49356 (N-methyl-2-(3-pyridil)-tetrahydrothiopyran-2-carbothiamide-1-oxide); $^{86}Rb/^{45}Ca$ fluxes; Pancreatic islets (Lebrun, P. (200) 159)

Insulin secretion
α-Adrenoceptors; Noradrenaline; Prazosin; Idazoxan; Phenylephrine (Gregersen, H. (200) 365)

Intestinal transport
Cl^- secretion; Arachidonic acid; Prostaglandins (MacNaughton, W.K. (200) 17)

Intracerebroventricular
Vocal behaviour; Scent-marking behaviour; Oxytocin; Vasopressin; (Monkey); (Neuropeptide) (Winslow, J. (200) 95)

Ion transport
Sulfates; Cell membranes; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Isoprenaline
Saphenous vein; α_2-Adrenoceptors; Congestive heart failure (Forster, C. (200) 251)

JO1784
Di-o-tolyl-guanidine; (+)-SKF 10,047; Hippocampus (rat); Acetylcholine release; σ Receptors; Phencyclidine (Junien, J.L. (200) 343)

KB-2796
Ca^{2+} channel antagonists; Dopamine; Stereotypy; Monoamine content; Dopamine turnover (Ozaki, A. (200) 311)

K^+ channel blockers
Tedisamil; Glibenclamide; K^+ channel openers; Cromakalim; Aorta (rat) (Bray, K. (200) 163)

K^+ channel openers
K^+ channel blockers; Tedisamil; Glibenclamide; Cromakalim; Aorta (rat) (Bray, K. (200) 163)

Cromakalim (BRL 34915); Caffeine; Ryanodine; Ca^{2+} (mobilization of intracellular); Mesenteric resistance vessels (rat) (Quast, U. (200) 239)

Lipolysis
cAMP; Adipocytes; β_3-Adrenoceptors (atypical) (Hollenga, C. (200) 325)

Locomotion
Dopamine D_1 receptors; Dopamine; Denervation supersensitivity; Rotation; A-68930; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Maternal aggression
Psychotropic action; Diazepam; SM-3997; Anxiolytics; (Female mouse) (Yoshimura, H. (200) 147)

MDA (methylenedioxyamphetamine)
Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis (in vivo); MDMA (3,4-methylenedioxymethamphetamine); Neurotoxicity (Nash, J.F. (200) 53)

MDMA (3,4-methylenedioxymethamphetamine)
[^{3}H]5-HT; [^{3}H]Dopamine; [^{3}H]Norepinephrine; Uptake inhibition; Non-vesicular release (Johnson, M.P. (200) 9)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis (in vivo); MDA (methylenedioxyamphetamine); Neurotoxicity (Nash, J.F. (200) 53)

α-Ethyltryptamine (Monase); 5-HT neurotoxicity; p-Chloroamphetamine (PCA) (Huang, X. (200) 187)

Membrane stabilisation
DOI (1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane); Sciatic nerve (frog) (Martin, K.F. (200) 191)

Mesenteric artery
Ca^{2+} influx; α-Adrenoceptors; Smooth muscle (vascular) (Guan, Y.-Y. (200) 283)

Mesenteric resistance vessels (rat)
Cromakalim (BRL 34915); K^+ channel openers; Caffeine; Ryanodine; Ca^{2+} (mobilization of intracellular) (Quast, U. (200) 239)

Microdialysis
Dopamine release; 5-HT receptor agonists; m-CPP (1-(m-chlorophenyl)piperazine); TFMPP (trifluoromethylphenylpiperazine) (Facilitation) (Benloucif, S. (200) 1)

Dopamine; Dopamine D_2 receptors; Pramipexole (SND 919); Talipexole (B-HT 920); Sulpiride; SCH 23390; Striatum (Carter, A.J. (200) 65)

Valproate; 5-HT (5-hyddroxytryptamine, serotonin) (Whitton, P.S. (200) 167)

Dopamine release/overflow; β-Endorphin-(1-27); Nucleus accumbens; (Intracerebroventricular); (Rat) (Spanagel, R. (200) 319)

Microdialysis (in vivo)
Dopamine; 5-HT (5-hydroxytryptamine, serotonin); MDA (methylenedioxyamphetamine); MDMA (3,4-methylenedioxymethamphetamine); Neurotoxicity (Nash, J.F. (200) 53)

MK-447
Sulfates; Cell membranes; Ion transport; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; Red blood cells (human) (Garay, R.P. (200) 141)

MK-801
Electroshock (maximal); Antiepileptics; Seizures (Urbańska, E. (200) 277)

Monoamine content
KB-2796; Ca^{2+} channel antagonists; Dopamine; Stereotypy; Dopamine turnover (Ozaki, A. (200) 311)

Morphiceptin
MR-2266; MR-1452; MR-2033; Hypertension; κ-Opioid receptor antagonism (Kraft, K. (200) 219)

Morphine
Analgesic tolerance; U-50,488H; Spinal analgesia; κ Opioid receptors; Nor-binaltorphimine (Takahashi, M. (200) 293)

MR-1452
MR-2266; Morphiceptin; MR-2033; Hypertension; κ-Opioid receptor antagonism (Kraft, K. (200) 219)

MR-2033
MR-2266; MR-1452; Morphiceptin; Hypertension; κ-Opioid receptor antagonism (Kraft, K. (200) 219)

MR-2266
MR-1452; Morphiceptin; MR-2033; Hypertension; κ-Opioid receptor antagonism (Kraft, K. (200) 219)

Muscarinic receptor agonists
Muscarinic receptor antagonists; Neuronal activity; Cerebral cortex; (Modulation); (Rat) (Lin, Y. (200) 45)

Muscarinic receptor antagonists
Muscarinic receptor agonists; Neuronal activity; Cerebral cortex; (Modulation); (Rat) (Lin, Y. (200) 45)

Muscarinic receptors
Vascular endothelium; Coronary artery (bovine); Cholinergic vasodilatation; (Functional experiments in vitro) (Brunner, F. (200) 25)

Muscle contractions
HI-6; Acetylcholinesterase inhibition; Neuromuscular junction; Electrophysiology; Organophosphate; (Direct effect) (Melchers, B.P.C. (200) 331)

Na^+,K^+,Cl^- cotransport system
Sulfates; Cell membranes; Ion transport; Na^+ transport; Cl^- transport; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Na^+ pump
Contraction; Renal artery; Spontaneously hypertensive rat (SHR) (Sakai, Y. (200) 227)

Na^+ transport
Sulfates; Cell membranes; Ion transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Neuromuscular junction
HI-6; Acetylcholinesterase inhibition; Electrophysiology; Muscle contractions; Organophosphate; (Direct effect) (Melchers, B.P.C. (200) 331)

Neuronal activity
Muscarinic receptor agonists; Muscarinic receptor antagonists; Cerebral cortex; (Modulation); (Rat) (Lin, Y. (200) 45)

Neurotoxicity
Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis (in vivo); MDA (methylenedioxyamphetamine); MDMA (3,4-methylenedioxymethamphetamine) (Nash, J.F. (200) 53)

Neutral endopeptidase
Gastric fundus (rat); Non-adrenergic, non-cholinergic (NANC) neurotransmitters; VIP (vasoactive intestinal peptide); Thiorphan; Phosphoramidon (Smits, G.J. (200) 361)

Nitric oxide (NO)
cGMP; Platelets; Endothelial cells (cultured); Fibroblasts (RFL-6 cells); EDRF (endothelium-derived relaxing factor) (Kuhn, M. (200) 175)

Alveolar macrophages; Pleural macrophages; L-Arginine; Glucocorticoids; Pulmonary; (Rat) (Jorens, P.G. (200) 205)

N^G-Nitro-D-arginine
N^G-Nitro-L-arginine; L-Arginine; D-Arginine; Pressor effects (Wang, Y.-X. (200) 77)

N^G-Nitro-L-arginine
N^G-Nitro-D-arginine; L-Arginine; D-Arginine; Pressor effects (Wang, Y.-X. (200) 77)

Non-adrenergic, non-cholinergic (NANC) neurotransmitters
Gastric fundus (rat); VIP (vasoactive intestinal peptide); Neutral endopeptidase; Thiorphan; Phosphoramidon (Smits, G.J. (200) 361)

Non-vesicular release
[^{3}H]5-HT; [^{3}H]Dopamine; [^{3}H]Norepinephrine; Uptake inhibition; MDMA (3,4-methylenedioxymethamphetamine) (Johnson, M.P. (200) 9)

Noradrenaline
Insulin secretion; α-Adrenoceptors; Prazosin; Idazoxan; Phenylephrine (Gregersen, H. (200) 365)

[^{3}H]Norepinephrine
[^{3}H]5-HT; [^{3}H]Dopamine; Uptake inhibition; Non-vesicular release; MDMA (3,4-methylenedioxymethamphetamine) (Johnson, M.P. (200) 9)

Nor-binaltorphimine
Analgesic tolerance; Morphine; U-50,488H; Spinal analgesia; κ Opioid receptors (Takahashi, M. (200) 293)

Nucleus accumbens
Dopamine release/overflow; Microdialysis; β-Endorphin-(1-27); (Intracerebroventricular); (Rat) (Spanagel, R. (200) 319)

8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)
Behaviour; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptors; Flesinoxan; (Rat) (Ahlenius, S. (200) 259)

5-HT_{1A} receptors; Corticosterone; Sex differences; Estradiol (Matsuda, T. (200) 299)

5-HT (5-hydroxytryptamine, serotonin); Sympathetic activity; Unit activity (King, K.A. (200) 357)

Open field
FG 7142; Benzodiazepine inverse agonists; Anxiogenic activity; Anxiety; (Rat) (Bruhwyler, J. (200) 183)

κ-Opioid receptor antagonism
MR-2266; MR-1452; Morphiceptin; MR-2033; Hypertension (Kraft, K. (200) 219)

Opioid receptors
Cholecystokinin (CCK); CCK analogues; CCK-B receptors; Radioligand binding; Analgesia (Slaninova, J. (200) 195)

δ-Opioid receptors
μ-Opioid receptors; Hypothalimic–pituitary–adrenocortical (HPA) axis; DAGO ([D-Ala^2,N-MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Gonzalvez, M.L. (200) 155)

κ-Opioid receptors
Spiradoline; Rotational behaviour; SKF 38393; Quinpirole; Striatum (Engber, T.M. (200) 171)

Analgesic tolerance; Morphine; U-50,488H; Spinal analgesia; Nor-binaltorphimine (Takahashi, M. (200) 293)

μ-Opioid receptors
δ-Opioid receptors; Hypothalimic–pituitary–adrenocortical (HPA) axis; DAGO ([D-Ala^2,N-MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin) (Gonzalvez, M.L. (200) 155)

Organophosphate
HI-6; Acetylcholinesterase inhibition; Neuromuscular junction; Electrophysiology; Muscle contractions; (Direct effect) (Melchers, B.P.C. (200) 331)

Oxygen consumption
Autonomic receptors; cAMP; cGMP; Parotid gland (rat); Antidepressants (Glenert, U. (200) 113)

Oxytocin
Vocal behaviour; Scent-marking behaviour; Intracerebroventricular; Vasopressin; (Monkey); (Neuropeptide) (Winslow, J. (200) 95)

Pancreatic islets
RP 49356 (N-methyl-2-(3-pyridil)-tetrahydrothiopyran-2-carbothiamide-1-oxide); $^{86}\text{Rb}/^{45}\text{Ca}$ fluxes; Insulin release (Lebrun, P. (200) 159)

Parasympathetic control
Dopaminergic control; Vagal bradycardia; Dopamine receptors; Dopamine receptor agonists (Roquebert, J. (200) 59)

Parotid gland (rat)
Autonomic receptors; cAMP; cGMP; Oxygen consumption; Antidepressants (Glenert, U. (200) 113)

Peptidases
Airway secretion; Airflow obstruction; Plasma exudation; (Guinea-pig) (Lötvall, J.O. (200) 211)

Peripheral-type benzodiazepine binding sites
[^{11}C]PK 11195; Binding (in vivo); PET (positron emission tomography) (Petit-Taboué, M.-C. (200) 347)

PET (positron emission tomography)
Peripheral-type benzodiazepine binding sites; [^{11}C]PK 11195; Binding (in vivo) (Petit-Taboué, M.-C. (200) 347)

Phencyclidine
JO1784; Di-o-tolyl-guanidine; (+)-SKF 10,047; Hippocampus (rat); Acetylcholine release; σ Receptors (Junien, J.L. (200) 343)

Phenoxybenzamine
Insulin-induced drinking; Water intake; Propranolol; Atenolol; Butoxamine (Lopez-Sela, P. (200) 125)

Phenylephrine
Insulin secretion; α-Adrenoceptors; Noradrenaline; Prazosin; Idazoxan (Gregersen, H. (200) 365)

Phorbol dibutyrate
Adenosine; Aorta (rabbit); Ca^{2+} channels (receptor-operated); Ca^{2+} channels (voltage-operated) (Urquhart, R.A. (200) 35)

Phosphodiesterase inhibitors
EDRF (endothelium-derived relaxing factor); cGMP; Zaprinast; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (200) 83)

Phospholipase C
Cl^- secretion; Ca^{2+}; Protein kinase C (Diener, M. (200) 267)

Phosphoramidon
Gastric fundus (rat); Non-adrenergic, non-cholinergic (NANC) neurotransmitters; VIP (vasoactive intestinal peptide); Neutral endopeptidase; Thiorphan (Smits, G.J. (200) 361)

[^{11}C]PK 11195
Peripheral-type benzodiazepine binding sites; Binding (in vivo); PET (positron emission tomography) (Petit-Taboué, M.-C. (200) 347)

Plasma catecholamines
Bradykinin; Bradykinin antagonists; (Conscious rat) (Bao, G. (200) 179)

Plasma exudation
Airway secretion; Airflow obstruction; Peptidases; (Guinea-pig) (Lötvall, J.O. (200) 211)

Platelets
Nitric oxide (NO); cGMP; Endothelial cells (cultured); Fibroblasts (RFL-6 cells); EDRF (endothelium-derived relaxing factor) (Kuhn, M. (200) 175)

Pleural macrophages
Alveolar macrophages; L-Arginine; Glucocorticoids; Nitric oxide (NO); Pulmonary; (Rat) (Jorens, P.G. (200) 205)

Pramipexole (SND 919)
Dopamine; Microdialysis; Dopamine D_2 receptors; Talipexole (B-HT 920); Sulpiride; SCH 23390; Striatum (Carter, A.J. (200) 65)

Prazosin
Insulin secretion; α-Adrenoceptors; Noradrenaline; Idazoxan; Phenylephrine (Gregersen, H. (200) 365)

Pressor effects
N^G-Nitro-L-arginine; N^G-Nitro-D-arginine; L-Arginine; D-Arginine (Wang, Y.-X. (200) 77)

Propranolol
Insulin-induced drinking; Water intake; Atenolol; Butoxamine; Phenoxybenzamine (Lopez-Sela, P. (200) 125)

Prostaglandins
Cl^- secretion; Arachidonic acid; Intestinal transport (MacNaughton, W.K. (200) 17)

Toluene diisocyanate; Asthma; Sensory nerves (Mapp, C.E. (200) 73)

Protein kinase C
Phospholipase C; Cl^- secretion; Ca^{2+} (Diener, M. (200) 267)

Psychotropic action
Maternal aggression; Diazepam; SM-3997; Anxiolytics; (Female mouse) (Yoshimura, H. (200) 147)

Pulmonary
Alveolar macrophages; Pleural macrophages; L-Arginine; Glucocorticoids; Nitric oxide (NO); (Rat) (Jorens, P.G. (200) 205)

Quinpirole
κ-Opioid receptors; Spiradoline; Rotational behaviour; SKF 38393; Striatum (Engber, T.M. (200) 171)

Radioligand binding
Cholecystokinin (CCK); CCK analogues; Opioid receptors; CCK-B receptors; Analgesia (Slaninova, J. (200) 195)

$^{86}Rb/^{45}Ca$ fluxes
RP 49356 (N-methyl-2-(3-pyridil)-tetrahydrothiopyran-2-carbothiamide-1-oxide); Insulin release; Pancreatic islets (Lebrun, P. (200) 159)

σ Receptors
JO1784; Di-o-tolyl-guanidine; (+)-SKF 10,047; Hippocampus (rat); Acetylcholine release; Phencyclidine (Junien, J.L. (200) 343)

Red blood cells (human)
Sulfates; Cell membranes; Ion transport; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447 (Garay, R.P. (200) 141)

Renal artery
Contraction; Na^+ pump; Spontaneously hypertensive rat (SHR) (Sakai, Y. (200) 227)

Rotation
Dopamine D_1 receptors; Dopamine; Denervation supersensitivity; Locomotion; A-68930; l-DOPA (l-dihydroxyphenylalanine); SK&F 38393 (Britton, D.R. (200) 89)

Rotational behaviour
κ-Opioid receptors; Spiradoline; SKF 38393; Quinpirole; Striatum (Engber, T.M. (200) 171)

RP 49356 (N-methyl-2-(3-pyridil)-tetrahydrothiopyran-2-carbothiamide-1-oxide)
$^{86}Rb/^{45}Ca$ fluxes; Insulin release; Pancreatic islets (Lebrun, P. (200) 159)

Ryanodine
Cromakalim (BRL 34915); K^+ channel openers; Caffeine; Ca^{2+} (mobilization of intracellular); Mesenteric resistance vessels (rat) (Quast, U. (200) 239)

Saphenous vein
Isoprenaline; α_2-Adrenoceptors; Congestive heart failure (Forster, C. (200) 251)

Scent-marking behaviour
Vocal behaviour; Intracerebroventricular; Oxytocin; Vasopressin; (Monkey); (Neuropeptide) (Winslow, J. (200) 95)

SCH 23390
Dopamine; Microdialysis; Dopamine D_2 receptors; Pramipexole (SND 919); Talipexole (B-HT 920); Sulpiride; Striatum (Carter, A.J. (200) 65)

Sciatic nerve (frog)
DOI (1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane); Membrane stabilisation (Martin, K.F. (200) 191)

Seizures
Electroshock (maximal); MK-801; Antiepileptics (Urbańska, E. (200) 277)

Sensory nerves
Toluene diisocyanate; Asthma; Prostaglandins (Mapp, C.E. (200) 73)

Sex differences
5-HT_{1A} receptors; 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Corticosterone; Estradiol (Matsuda, T. (200) 299)

Single neuron recordings (extracellular)
Dopamine; Ventral pallidum; Substantia innominata; Dopamine D_1 receptors; Dopamine D_2 receptors (Maslowski, R.J. (200) 103)

SK&F 38393
Dopamine D_1 receptors; Dopamine; Denervation supersensitivity; Rotation; Locomotion; A-68930; l-DOPA (l-dihydroxyphenylalanine) (Britton, D.R. (200) 89)

SKF 38393
κ-Opioid receptors; Spiradoline; Rotational behaviour; Quinpirole; Striatum (Engber, T.M. (200) 171)

(+)-SKF 10,047
JO1784; Di-o-tolyl-guanidine; Hippocampus (rat); Acetylcholine release; σ Receptors; Phencyclidine (Junien, J.L. (200) 343)

SM-3997
Maternal aggression; Psychotropic action; Diazepam; Anxiolytics; (Female mouse) (Yoshimura, H. (200) 147)

Smooth muscle (vascular)
Ca^{2+} influx; α-Adrenoceptors; Mesenteric artery (Guan, Y.-Y. (200) 283)

Spinal analgesia
Analgesic tolerance; Morphine; U-50,488H; κ Opioid receptors; Nor-binaltorphimine (Takahashi, M. (200) 293)

Spiradoline
κ-Opioid receptors; Rotational behaviour; SKF 38393; Quinpirole; Striatum (Engber, T.M. (200) 171)

Spontaneously hypertensive rat (SHR)
EDRF (endothelium-derived relaxing factor); cGMP; Phosphodiesterase inhibitors; Zaprinast; Blood pressure (Dundore, R.L. (200) 83)

Contraction; Na^+ pump; Renal artery (Sakai, Y. (200) 227)

Dopamine receptors; α-Adrenoceptors (Brooks, D.P. (200) 339)

Stereotypy
KB-2796; Ca^{2+} channel antagonists; Dopamine; Monoamine content; Dopamine turnover (Ozaki, A. (200) 311)

Striatum
Dopamine; Microdialysis; Dopamine D_2 receptors; Pramipexole (SND 919); Talipexole (B-HT 920); Sulpiride; SCH 23390 (Carter, A.J. (200) 65)

κ-Opioid receptors; Spiradoline; Rotational behaviour; SKF 38393; Quinpirole (Engber, T.M. (200) 171)

Substantia innominata
Dopamine; Ventral pallidum; Dopamine D_1 receptors; Dopamine D_2 receptors; Single neuron recordings (extracellular) (Maslowski, R.J. (200) 103)

Sulfates
Cell membranes; Ion transport; Na^+ transport; Cl^- transport; Na^+,K^+,Cl^- cotransport system; Diuretics; MK-447; Red blood cells (human) (Garay, R.P. (200) 141)

Sulpiride
Dopamine; Microdialysis; Dopamine D_2 receptors; Pramipexole (SND 919); Talipexole (B-HT 920); SCH 23390; Striatum (Carter, A.J. (200) 65)

Sympathetic activity
5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Unit activity (King, K.A. (200) 357)

Talipexole (B-HT 920)
Dopamine; Microdialysis; Dopamine D_2 receptors; Pramipexole (SND 919); Sulpiride; SCH 23390; Striatum (Carter, A.J. (200) 65)

Tedisamil
K^+ channel blockers; Glibenclamide; K^+ channel openers; Cromakalim; Aorta (rat) (Bray, K. (200) 163)

Temporal cortex (human)
Angiotensin converting enzyme; Alzheimer's disease (Barnes, N.M. (200) 289)

TFMPP (trifluoromethylphenylpiperazine) (Facilitation)
Dopamine release; 5-HT receptor agonists; Microdialysis; m-CPP (1-(m-chlorophenyl)piperazine) (Benloucif, S. (200) 1)

Thiorphan
Gastric fundus (rat); Non-adrenergic, non-cholinergic (NANC) neurotransmitters; VIP (vasoactive intestinal peptide); Neutral endopeptidase; Phosphoramidon (Smits, G.J. (200) 361)

Toluene diisocyanate
Asthma; Sensory nerves; Prostaglandins (Mapp, C.E. (200) 73)

U-50,488H
Analgesic tolerance; Morphine; Spinal analgesia; κ Opioid receptors; Nor-binaltorphimine (Takahashi, M. (200) 293)

Unit activity
5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin); Sympathetic activity (King, K.A. (200) 357)

Uptake inhibition
[^{3}H]5-HT; [^{3}H]Dopamine; [^{3}H]Norepinephrine; Non-vesicular release; MDMA (3,4-methylenedioxymethamphetamine) (Johnson, M.P. (200) 9)

Vagal bradycardia
Parasympathetic control; Dopaminergic control; Dopamine receptors; Dopamine receptor agonists (Roquebert, J. (200) 59)

Valproate
5-HT (5-hyddroxytryptamine, serotonin); Microdialysis (Whitton, P.S. (200) 167)

Vascular endothelium
Muscarinic receptors; Coronary artery (bovine); Cholinergic vasodilatation; (Functional experiments in vitro) (Brunner, F. (200) 25)

Vasopressin
Vocal behaviour; Scent-marking behaviour; Intracerebroventricular; Oxytocin; (Monkey); (Neuropeptide) (Winslow, J. (200) 95)

Vasorelaxation
BNP (brain natriuretic polypeptide); ANP (atrial natriuretic polypeptide); Diuresis; cGMP; (Receptor) (Furuya, M. (200) 233)

Ventral pallidum
Dopamine; Substantia innominata; Dopamine D_1 receptors; Dopamine D_2 receptors; Single neuron recordings (extracellular) (Maslowski, R.J. (200) 103)

Verapamil
Cardiac protein kinase C; Diabetes; (Rat) (Tanaka, Y. (200) 353)

VIP (vasoactive intestinal peptide)
Gastric fundus (rat); Non-adrenergic, non-cholinergic (NANC) neurotransmitters; Neutral endopeptidase; Thiorphan; Phosphoramidon (Smits, G.J. (200) 361)

Vocal behaviour
Scent-marking behaviour; Intracerebroventricular; Oxytocin; Vasopressin; (Monkey); (Neuropeptide) (Winslow, J. (200) 95)

Water intake
Insulin-induced drinking; Propranolol; Atenolol; Butoxamine; Phenoxybenzamine (Lopez-Sela, P. (200) 125)

Zaprinast
EDRF (endothelium-derived relaxing factor); cGMP; Phosphodiesterase inhibitors; Blood pressure; Spontaneously hypertensive rat (SHR) (Dundore, R.L. (200) 83)